Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness

References

1. ↵
   1. Hallek M,
   2. Pflug N

   (2010) Chronic lymphocytic leukemia. Ann Oncol 21:vii154–vii164.

   OpenUrlCrossRefPubMed
2. ↵
   1. Rozman C,
   2. Montserrat E

   (1995) Chronic lymphocytic leukemia. N Engl J Med 333:1052–1057.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Hallek M

   (2015) Chronic lymphocytic leukemia:2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 90:446–460.

   OpenUrlCrossRefPubMed
4. ↵
   1. Nabhan C,
   2. Rosen ST

   (2014) Chronic lymphocytic leukemia:a clinical review. JAMA 312:2265–2276.

   OpenUrlCrossRefPubMed
5. ↵
   1. Alsagaby SA,
   2. Brennan P,
   3. Pepper C

   (2016) Key Molecular Drivers of Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 16:593–606.

   OpenUrl
6. ↵
   1. Hamblin TJ,
   2. Davis Z,
   3. Gardiner A,
   4. Oscier DG,
   5. Stevenson FK

   (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Dürig J,
   2. Naschar M,
   3. Schmücker U,
   4. Renzing-Köhler K,
   5. Hölter T,
   6. Hüttmann A,
   7. et al.

   (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16:30–35.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Rassenti LZ,
   2. Huynh L,
   3. Toy TL,
   4. Chen L,
   5. Keating MJ,
   6. Gribben JG,
   7. et al.

   (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893–901.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Döhner H,
   2. Stilgenbauer S,
   3. Benner A,
   4. Leupolt E,
   5. Kröber A,
   6. Bullinger L,
   7. et al.

   (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Mertens D,
    2. Stilgenbauer S

    (2014) Prognostic and predictive factors in patients with chronic lymphocytic leukemia:relevant in the era of novel treatment approaches? J Clin Oncol 32:869–872.

    OpenUrlFREE Full Text
11. ↵
    1. Alsagaby SA,
    2. Alhumaydhi FA

    (2019) Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. Saudi Med J 40:179–189.

    OpenUrl
12. ↵
    1. Alsagaby SA,
    2. Khanna S,
    3. Hart KW,
    4. Pratt G,
    5. Fegan C,
    6. Pepper C,
    7. et al.

    (2014) Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. J Proteome Res 13:5051–5062.

    OpenUrlCrossRefPubMed
13. ↵
    1. Alsagaby S,
    2. Brewis I,
    3. Pepper C,
    4. Fegan C,
    5. Brennan P

    (2010) Analysis of human B-cells with quantitative and sub-cellular proteomics. Immunology 131:115.

    OpenUrl
14. ↵
    1. Gene Expression Omnibus [Internet]

    National Centre for Biotechnology Information. NCBI, Available from: https://www.ncbi.nlm.nih.gov/geo/. [Accessed 10 July 2018].
15. ↵
    1. National Cancer Institute

    The Cancer Genome Atlas. NIH, Available from: https://cancergenome.nih.gov/. [Accessed 2018 July 23].
16. ↵
    1. Chuang HY,
    2. Rassenti L,
    3. Salcedo M,
    4. Licon K,
    5. Kohlmann A,
    6. Haferlach T,
    7. et al.

    (2012) Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 120:2639–2649.

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Herold T,
    2. Jurinovic V,
    3. Metzeler KH,
    4. Boulesteix AL,
    5. Bergmann M,
    6. Seiler T,
    7. et al.

    (2011) An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25:1639–1645.

    OpenUrlCrossRefPubMed
18. ↵
    1. Reimand J,
    2. Arak T,
    3. Adler P,
    4. Kolberg L,
    5. Reisberg S,
    6. Peterson H,
    7. et al.

    (2016) g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res 44:W83–W89.

    OpenUrlCrossRefPubMed
19. 1. Pundir S,
    2. Martin MJ,
    3. O'Donovan C

    (2016) UniProt Tools. Curr Protoc Bioinformatics 53:1–15.

    OpenUrl
20. ↵
    1. UniProt

    The UniProt Consortium, The universal protein knowledgebase [Internet]. Available from: https://www.uniprot.org/. [Accessed 2018 July 1].
21. ↵
    1. Gao J,
    2. Aksoy BA,
    3. Dogrusoz U,
    4. Dresdner G,
    5. Gross B,
    6. Sumer SO,
    7. et al.

    (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:l1.

    OpenUrl
22. ↵
    1. Croft D,
    2. Mundo AF,
    3. Haw R,
    4. Milacic M,
    5. Weiser J,
    6. Wu G,
    7. et al.

    (2014) The Reactome pathway knowledgebase. Nucleic Acids Res 42:D472–D477.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Babicki S,
    2. Arndt D,
    3. Marcu A,
    4. Liang Y,
    5. Grant JR,
    6. Maciejewski A,
    7. et al.

    (2016) Heatmapper:web-enabled heat mapping for all. Nucleic Acids Res 44:W147–W153.

    OpenUrlCrossRefPubMed
24. ↵
    1. Shilo A,
    2. Siegfried Z,
    3. Karni R

    (2014) The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. Mol Cell Oncol 2:e970955.

    OpenUrl
25. ↵
    1. Barboro P,
    2. Ferrari N,
    3. Balbi C

    (2014) Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression. Cancer Lett 352:152–159.

    OpenUrlCrossRefPubMed
26. ↵
    1. Geng Y,
    2. Zhang L,
    3. Xu M,
    4. Sheng W,
    5. Dong A,
    6. Cao J,
    7. et al.

    (2015) [The expression and significance of hnRNPD in esophageal squamous cell carcinoma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 31:1659–1663, [Chinese].

    OpenUrl
27. ↵
    1. Chen CY,
    2. Chuang YS,
    3. Pi WC,
    4. Wang TC

    (2014) HnRNP A2/B1 regulates alternative splicing of Tid1 isoforms. The FASEB Journal 28:742.

    OpenUrl
28. ↵
    1. Revil T,
    2. Pelletier J,
    3. Toutant J,
    4. Cloutier A,
    5. Chabot B

    (2009) Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J Biol Chem 284:21458–21467.

    OpenUrlAbstract/FREE Full Text
29. ↵
    1. Izquierdo JM

    (2010) Heterogeneous ribonucleoprotein C displays a repressor activity mediated by T-cell intracellular antigen-1-related/like protein to modulate Fas exon 6 splicing through a mechanism involving Hu antigen R. Nucleic Acids Res 38:8001–8014.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    1. Johnston HE,
    2. Carter MJ,
    3. Larrayoz M,
    4. Clarke J,
    5. Garbis SD,
    6. Oscier D,
    7. et al.

    (2018) Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation. Mol Cell Proteomics 17:776–791.

    OpenUrlAbstract/FREE Full Text
31. ↵
    1. Messmer BT,
    2. Messmer D,
    3. Allen SL,
    4. Kolitz JE,
    5. Kudalkar P,
    6. Cesar D,
    7. et al.

    (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755–764.

    OpenUrlCrossRefPubMedWeb of Science
32. ↵
    1. Pepper C,
    2. Hewamana S,
    3. Brennan P,
    4. Fegan C

    (2009) NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 5:1027–1037.

    OpenUrlPubMed
33. ↵
    1. Stevenson FK,
    2. Krysov S,
    3. Davies AJ,
    4. Steele AJ,
    5. Packham G

    (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118:4313–4320.

    OpenUrlAbstract/FREE Full Text
34. ↵
    1. Shachar I,
    2. Cohen S,
    3. Marom A,
    4. Becker-Herman S

    (2012) Regulation of CLL survival by hypoxia-inducible factor and its target genes. FEBS Lett 586:2906–2910.

    OpenUrlCrossRefPubMed
35. ↵
    1. Krejci P,
    2. Pejchalova K,
    3. Rosenbloom BE,
    4. Rosenfelt FP,
    5. Tran EL,
    6. Laurell H,
    7. et al.

    (2007) The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leukoc Biol 82:1363–1364.

    OpenUrlCrossRefPubMedWeb of Science
36. ↵
    1. Del Gaizo Moore V,
    2. Brown JR,
    3. Certo M,
    4. Love TM,
    5. Novina CD,
    6. Letai A

    (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112–121.

    OpenUrlCrossRefPubMedWeb of Science
37. ↵
    1. Secchiero P,
    2. Voltan R,
    3. di Iasio MG,
    4. Melloni E,
    5. Tiribelli M,
    6. Zauli G

    (2010) The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res 16:1824–1833.

    OpenUrlAbstract/FREE Full Text
38. ↵
    1. Geuens T,
    2. Bouhy D,
    3. Timmerman V

    (2016) The hnRNP family:insights into their role in health and disease. Hum Genet 135:851–867.

    OpenUrlCrossRefPubMed
39. ↵
    1. Alsagaby SA

    (2019) Integration of proteomics and transcriptomics data sets identifies prognostic markers in chronic lymphocytic leukemia. Majmaah Journal of Health Sciences 7:1–22.

    OpenUrl
40. ↵
    1. Gry M,
    2. Rimini R,
    3. Strömberg S,
    4. Asplund A,
    5. Pontén F,
    6. Uhlén M,
    7. et al.

    (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10:365.

    OpenUrlCrossRefPubMed